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Abstract
Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123I-MIBG and 
131I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124I-metaiodobenzylguanidine (MIBG) 
positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124I-MIBG PET/CT: 
two pediatric patients affected by neuroblastoma, who underwent 124I-MIBG PET/CT for pre-therapy distribution evaluation and 
restaging purposes. We aimed to evaluate whether 124I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 
123I/131I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124I-MIBG PET/CT 
are required.
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Background
Neuroblastoma (NB) is the most common extra-cranial 
solid tumor in pediatric patients and originates from sympa-
thetic cells derived from the neural crest. Bone and bone marrow 
metastases are quite common and, if present, result in a poor 
prognosis [1, 2]. Many studies have been reported the important 
role of 123I-Meta-iodobenzylguanidine (MIBG) at the time of first 
staging and at the evaluation of treatment response, especially 
after induction chemotherapy [3–5]. Moreover, 123I-MIBG scan 
is required when NB relapse is suspected and may establish the 
basis for the use of a targeted radionuclide therapy with 131I-MIBG 
[6]. The principal limitation of conventional nuclear medicine in 
neuroblastoma (mainly 123I-MIBG scan) is related to its relative 
low spatial resolution when compared with other radiological and 
functional techniques such as CT, MRI and PET, similarly to what 
happens in other pediatric tumors [7–13].
MIBG labeled with 124I, a positron emitting isotope suitable for PET 
imaging, got increased interest in clinical practice [14–17]. The target 
of this radiocompound should be the capability of binding noradrena-
lin receptors as it happens with 123I-MIBG, but with a higher image 
quality and sensitivity granted by PET hardware [14]. However, limited 
data exist about the diagnostic accuracy of 124I-MIBG PET in NB.
We present the preliminary experience of the PET Pediatric 
AIMN (Italian Association of Nuclear Medicine) InterGroup with 
124I-MIBG PET/CT in two pediatric patients diagnosed with neuro-
blastoma in order to highlight the improvement in diagnostic ac-
curacy provided by 124I-MIBG PET/CT compared to the conventional 
imaging work-up assessing whether 124I-MIBG PET/CT could detect 
as many or more neuroblastoma lesions than 123I/131I-MIBG imaging.
Case series
Case 1. Taking advantage of the better  
spatial resolution of 124I-MIBG PET/CT
Patient No. 1 (10-year-old female) came to our observation with 
diagnosis of poorly differentiated abdominal neuroblastoma — stage 
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III — with involvement of the left kidney and the homolateral adrenal 
gland. The patient had undergone neoadjuvant chemotherapy 
(cisplatin, etoposide and VP 16) before radical resection of the large 
abdominal mass. One year after surgery, the patient was referred for 
131I-MIBG therapy (dose: 10 GBq) for a pulmonary relapse detected 
by a computed tomography (CT) exam. The 123I-MIBG pre-therapy 
and the 131I-post-therapy whole body scans depicted a single focal 
round-shaped uptake in the right lung. A week later, the child was pro-
posed to scan with the experimental radiopharmaceutical 124I-MIBG for 
compassionate use, regulated by Legislative Decree No. 219/2006. 
After receiving written consent from the parents, the patient was evalu-
ated by PET/CT at 24h and 48h after the administration of 50 MBq of 
124I-MIBG (radiochemical purity > 95%) (Fig. 1). The PET/CT study 
(Fig. 2) confirmed the finding detected by both 123I-MIBG scintigraphy 
and 131I-post-therapy whole body scan allowing a better characteriza-
tion and localization of the finding in the basis of the right lung.
Afterwards, the patient underwent metastasectomy and the di-
sease had a favorable course confirmed by a subsequent 123I-MIBG 
scintigraphy and a chest CT performed three and six months later, 
respectively. Nevertheless, the patient developed lumbar pain and 
signs of paraparesis a few months later, and a whole body CT with 
contrast medium revealed diffuse metastases to both lungs, ab-
dominal lymph nodes and the fifth lumbar vertebra. Therefore the 
patient was referred for a second course of 131I-MIBG therapy. The 
131I-MIBG post-therapy whole body scan (Fig. 3) was able to high-
light all the lesions demonstrated by the CT scan, but pre-therapy 
124I-MIBG PET/CT yielded a very good definition of the extent of di-
sease (Fig. 4), demonstrating also the involvement of the medullary 
canal by the lesion located in the L3 vertebra, explaining the origin 
of the symptomatology of the patient, and revealed faint foci in L1, 
L4, L5 and sacrum (Fig. 5). On the basis of the clinical condition 
and imaging findings, the patient underwent a further treatment with 
131I-MIBG, with a delivered dose of 10 GBq (270 mCi).
Figure 2A–C. Axial 123I-MIBG 24 h-SPECT image (A) and PET/CT fusion images taken at 24h (B) and 48h (C) documented the pulmonary lesion in 
the right lower pulmonary lobe. Of note the increased uptake over the time in the 124I-MIBG PET/CT images
Figure 1A–F. 123I-MIBG planar images (A, B): posterior images, 
after 4 h (A) and 24 h (B) from radiopharmaceutical intravenous 
administration, documenting a lesion in the posterior region of the 
right pulmonary basis. 131I-MIBG post-therapy scan (C, D): anterior 
images, acquired 24 h (C) and 48 h (D) after injection. Uptake in the 
right lung is consistent with pulmonary recurrence. 124I-MIBG Maximum 
Intensity Projection (MIP) images after 24h (E) and 48h (F) show the 
same finding
Figure 3A–C. Multiple pulmonary lesions evidenced by the 124I-MIBG 
PET/CT Maximum Intensity Projection (MIP) image (A) and the 
posterior views of 131I-MIBG post-therapy scan acquired 24 h (B) and 
48 h (C) after injection
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Case 2. Depiction of all metastatic sites in one 
single full-body exam
Patient No. 2 was a 6-year-old boy with left adrenal gland 
neuroblastoma (stage IV) diagnosed when he was 1-year-old. The 
pathologic history had showed persistent bone disease involvement 
although the patient had already been treated with surgery, radio-
therapy, chemotherapy and auto-transplantation over the years. After 
performing a follow-up 123I-MIBG scintigraphy in another center for 
restaging purposes, he was referred to our department to receive 
Figure 4A. Sagittal CT, 124I-MIBG PET and fused PET/CT images; B. Axial co-registered CT image at the level of the third lumbar vertebra; C. Axial 
124I-MIBG PET/CT view of L3. 124I-MIBG PET/CT shows the same metastatic involvement of L3, as shown in figure 3 but with a dramatically improved 
definition, demonstrating the intracanal and the extra canal components of the lesion
Figure 5A–D. Multiple metastatic lesions in patient No. 1 highlighted by 124I-MIBG PET/CT: L1 (A), L4 (B), L5 (C) and sacrum (D)
a course of 9.9 GBq (270 mCi) 131I-MIBG. The 131I-MIBG post-therapy 
scan showed diffuse osseous disease (Fig. 6A, B) including the skull, 
the left scapula, several vertebrae, the right and left iliac bones, the 
ischiatic spine, the proximal part of the left tibia and the bone mar-
row canal of the right femur. After gaining informed consent from the 
patient, 124I-MIBG PET/CT was also performed for compassionate 
use and was able to visualize the same lesions as detected by the 
planar scintigraphy with 131I-MIBG (Fig. 6C–F) clearly providing ima-
ges with better spatial resolution in all the bone districts.
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Discussion
Although MIBG, radiolabeled with 123I, has high sensitivity 
(around 90%) and specificity close to 100% in the diagnosis of 
neuroblastoma [17], nevertheless an important role of labeled 
MIBG is also prospectively to evaluate the feasibility of 131I-MIBG 
radiometabolic therapy, which can be an additional therapeutic 
option in case of disseminated metastatic disease in which tumor 
cells have retained the capability of concentrating MIBG [6].
From this point of view, 124I-MIBG PET/CT represents a poten-
tial method to estimate radiation dose to normal organs, as well 
as tumors, prior to 131I-MIBG treatment and provide a more ac-
curate quantification of tracer distribution because of its favorable 
characteristics, such as full-body tomographic capability from PET 
and a similar half-life (4.2 days) to 131I (8.02 days) [15].
Despite this important aspect, only few reports published in 
literature regarded the use of 124I-MIBG in adult patients with neural 
crest tumors [14, 16] and, to the best of our knowledge, only one 
child with neuroblastoma has been studied with 124I-MIBG PET/CT 
so far [18], providing data on dosimetry. Organ-absorbed doses for 
the salivary glands, heart wall and liver were 98.0 Gy, 36.5 Gy, 
and 34.3 Gy, respectively, whereas tumor-absorbed dose range 
was 143.9–1,641.3 Gy [18].
Many other studies investigated the role of PET/CT using other 
tracers such as 18F-DOPA [7, 19], 68Ga-labelled somatostatin ana-
logues and 18F-FDG in patients with neuroblastoma [20]. Anyway, 
although these tracers can provide an excellent diagnostic accuracy 
in patients affected by neuroblastoma, nevertheless the labeled 
pharmaceutical has a metabolic behavior which is similar but not 
equal to iodine-labeled MIBG.
In our series, we investigated if 124I-MIBG PET/CT could be 
considered a valuable tool in the diagnostic work-up of pediatric 
patient with advanced neuroblastoma.
From our experience, 124I-MIBG PET/CT provides high-reso-
lution images and may offer valuable information regarding the 
extension of the lesion and the involvement of different types of 
tissue, addressing the most appropriate clinical management be-
tween surgical treatment and medical therapy [21]. In the present 
study, with the limit of lack of SPECT/CT, we could compare in our 
patients images obtained with 123I-MIBG scintigraphy, 131I-MIBG 
scintigraphy and with 124I-MIBG PET/CT, with the latter providing 
the same e information about the tumor location in the case of the 
single round-shaped pulmonary lesion (patient n. 1).
In patient No. 1, the first 124I-MIBG PET/CT not only confirmed 
the finding detected by both 123I-MIBG scintigraphy and 131I-MIBG 
post-therapy scan, but allowed a better characterization and 
localization of the finding in the basis of the right lung, helping 
the clinical staff in the decision of performing a metastasectomy. 
Furthermore, the second 124I-MIBG PET/CT, performed in case 
No. 1, provided a very accurate definition of the extent of disease 
demonstrating the intracanal and the extra canal components of 
the lesion located at the level of L3 and detected a higher number 
of lesion (L1, L4, L5 and sacrum) in comparison to 131I-MIBG and 
CT. The findings of 124I-MIBG PET/CT were useful for the clinicians to 
link the symptomatology of the patient (lumbar pain and signs of 
paraparesis) to the pathologic involvement of the medullar canal.
Figure 6A–F. 131I-MIBG post-therapy total body scan, anterior (A) and posterior (B) images: scintigraphic pattern consistent with multiple bone 
metastases (some of the lesions are evidenced by arrows: skull, pelvis and femur). 124I-MIBG PET/CT was also performed and was able to visualize 
the same number of metastases. Axial 124I-MIBG PET/CT fusion images showing some of the metastatic lesions with a dramatically improved 
definition; C. Skull; D–E. Pelvis; F. Right femur (an involvement of the left femur is also evident)
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Since metastatic spread of neuroblastoma may occur over the 
full length of the skeleton and since MIBG does not present uptake 
in the brain, 124I-MIBG gives excellent images of the skull and so 
is useful to detect secondary lesions in this anatomical region, 
which is a relatively frequent site of metastasis. Likewise, 124I-MIBG 
PET/CT should be performed in full body modality from the vertex 
of the skull to the feet.
A possible limitation in evaluating pediatric patients with 
124I-MIBG PET/CT is the relatively higher radiation dose delivered 
(0.25 mSv/MBq) when compared to 123I-MIBG (0.019 mSv/MBq). 
Nevertheless, the improved characteristics of modern PET/CT 
scanners allow limiting the administered dose while maintaining 
an adequate image quality [22]. Moreover, the additional dose can 
be considered negligible by comparison if 124I-MIBG is performed 
as a pre-therapy evaluation tool before 131I-MIBG treatment.
Although there is lack of information in literature, this preliminary 
experience shows promising results for 124I-MIBG PET/CT; anyway, 
a large validation and a standardization of the technique is needed, 
such as for the optimal timing of 124I-MIBG PET imaging acquisition.
Multicenter investigations would be desirable, in order to fos-
ter the possible role of this technique in evaluating patients with 
neuroblastoma. At present, we could at least suggest to perform 
a 124I-MIBG PET/CT as a pre-therapy examination, given the high 
diagnostic accuracy demonstrated by our cases, and for restaging, 
especially when doubtful findings are evidenced by scintigraphic 
imaging with 123I or 131I-MIBG.
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